

GCK Antibody (N-term)

Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AW5177

Specification

GCK Antibody (N-term) - Product Information

Application WB,E
Primary Accession P35557
Reactivity Human, Rat
Host Rabbit
Clonality Polyclonal

Calculated MW H=52;M=52;Rat=52,50 KDa

Isotype Rabbit IgG
Antigen Source HUMAN

GCK Antibody (N-term) - Additional Information

Gene ID 2645

Antigen Region

1-30

Other Names

GCK; Glucokinase; Hexokinase type IV; Hexokinase-4; Hexokinase-D

Dilution

WB~~1:1000

Target/Specificity

This GCK antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1-30 amino acids from the N-terminal region of human GCK.

Format

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

GCK Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.

GCK Antibody (N-term) - Protein Information

Name GCK {ECO:0000303|PubMed:17573900, ECO:0000312|HGNC:HGNC:4195}



Function

Catalyzes the phosphorylation of hexose, such as D-glucose, D-fructose and D-mannose, to hexose 6-phosphate (D-glucose 6-phosphate, D-fructose 6-phosphate and D-mannose 6-phosphate, respectively) (PubMed: 11916951, PubMed:15277402, PubMed:17082186, PubMed:18322640, PubMed:19146401, PubMed:25015100, PubMed:7742312, PubMed:8325892). Compared to other hexokinases, has a weak affinity for D-glucose, and is effective only when glucose is abundant (By similarity). Mainly expressed in pancreatic beta cells and the liver and constitutes a rate-limiting step in glucose metabolism in these tissues (PubMed:11916951, PubMed:15277402, PubMed:18322640, PubMed:25015100, PubMed:8325892). Since insulin secretion parallels glucose metabolism and the low glucose affinity of GCK ensures that it can change its enzymatic activity within the physiological range of glucose concentrations, GCK acts as a glucose sensor in the pancreatic beta cell (By similarity). In pancreas, plays an important role in modulating insulin secretion (By similarity). In liver, helps to facilitate the uptake and conversion of glucose by acting as an insulin-sensitive determinant of hepatic glucose usage (By similarity). Required to provide D-glucose 6-phosphate for the synthesis of glycogen (PubMed: 8878425). Mediates the initial step of glycolysis by catalyzing phosphorylation of D-glucose to D-glucose 6-phosphate (PubMed: 7742312).

Cellular Location

Cytoplasm. Nucleus. Mitochondrion {ECO:0000250|UniProtKB:P17712}. Note=Under low glucose concentrations, GCK associates with GCKR and the inactive complex is recruited to the hepatocyte nucleus.


GCK Antibody (N-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- <u>Immunohistochemistry</u>
- <u>Immunofluorescence</u>
- <u>Immunoprecipitation</u>
- Flow Cytomety
- Cell Culture

GCK Antibody (N-term) - Images





Western blot analysis of lysates from HepG2 cell line and rat liver tissue lysate(from left to right), using GCK Antibody (M1)(Cat. #AW5177). AW5177 was diluted at 1:1000 at each lane. A goat anti-rabbit IgG H&L(HRP) at 1:10000 dilution was used as the secondary antibody.

GCK Antibody (N-term) - Background

Hexokinases phosphorylate glucose to produce glucose-6-phosphate, thus committing glucose to the glycolytic pathway. Alternative splicing of the gene for GCK results in three tissue-specific forms of glucokinase, one found in pancreatic islet beta cells and two found in liver. The protein localizes to the outer membrane of mitochondria. In contrast to other forms of hexokinase, this enzyme is not inhibited by its product glucose-6-phosphate but remains active while glucose is abundant. Mutations in the gene have been associated with non-insulin dependent diabetes mellitus (NIDDM), also called maturity onset diabetes of the young, type 2 (MODY2); mutations have also been associated with persistent hyperinsulinemic hypoglycemia of infancy (PHHI).

GCK Antibody (N-term) - References

Gloyn, A.L., et al., Diabetes 52(9):2433-2440 (2003). Pruhova, S., et al., Diabetologia 46(2):291-295 (2003). Rizzo, M.A., et al., J. Biol. Chem. 277(37):34168-34175 (2002). Cao, H., et al., Hum. Mutat. 20(6):478-479 (2002). Barrio, R., et al., J. Clin. Endocrinol. Metab. 87(6):2532-2539 (2002).